Pipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...

GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

The candidate has been approved under the brand name Attruby. BBIO stock surged 16.1% on the FDA approval of the drug. BridgeBio’s shares have lost 32.6% in the year-to-date period against the ...

The candidate has been approved under the brand name Attruby. BBIO stock surged on the news. The FDA approval is based on positive results from the phase III ATTRibute-CM study, in which Attruby ...